Bayer Faces a Pivotal August as Earnings and a Delayed Court Hearing Converge

Bayer faces pivotal August with half-year results and a key glyphosate settlement hearing, while a $5B bond sale buys time and earnings are expected to swing to profit.

The next few weeks will be critical for Bayer, with two major events now clustered in August that could set the direction for the stock. The company will release its half-year results on August 4, followed just two weeks later by a long-awaited court hearing in Missouri over its proposed $7.25 billion glyphosate class-action settlement. The hearing, originally scheduled for early July, has been pushed back to August 19, leaving investors in limbo a little longer on a key piece of legal closure.

Shares ended last week at €46.01, down 4.48% for the period, reflecting the absence of fresh catalysts. The stock has been treading water as the market waits for clarity on both the financial and legal fronts.

A $5 Billion Bond Sale Buys Time

While the legal calendar shifted, Bayer moved decisively on the financing side. On July 15, the company placed new US dollar bonds worth $5 billion across five tranches with maturities ranging from five to 30 years. The issue was multiple times oversubscribed, signaling strong investor appetite for Bayer’s credit despite the ongoing litigation overhang.

The proceeds are intended to extend the maturity profile of upcoming debt. Net financial debt stood at €32.518 billion as of March 31, up from €29.8 billion at the end of 2025, driven largely by seasonal effects and payments tied to legal disputes. The refinancing gives the group more breathing room as it continues to manage its balance sheet.

Earnings Turnaround Expected

Analysts are forecasting a sharp improvement in second-quarter earnings. The consensus estimate points to earnings per share of €0.769, a significant swing from the €0.200 per share loss recorded in the same period last year. That turnaround, if confirmed, would underscore the operational progress Bayer has made in its core businesses even as legal uncertainties persist.

The quiet period ahead of the August 4 report means management will not comment on operational developments until the numbers are released.

Portfolio Moves and Analyst Divergence

Beyond the bond market, Bayer is reportedly nearing the sale of its contraceptive business, a deal that could be worth around €3 billion. Such a transaction would provide additional firepower for debt reduction and create more financial flexibility for the remaining litigation exposure.

Analyst views on the stock remain split. JPMorgan reiterated its "Overweight" rating with a €50 price target, citing the improved risk profile following a late-June US Supreme Court ruling that strengthened Bayer’s position on certain liability questions. Barclays is even more bullish with a €60 target, while Jefferies holds a more cautious €46 target, arguing that portfolio streamlining is a prerequisite for a lasting revaluation.

Technical Picture: Neutral Ground

From a chart perspective, the stock is in a holding pattern. The relative strength index sits at 49.6, squarely in neutral territory after an overbought reading in early July faded. The 50-day moving average at €42.14 represents the key downside support level, while the fact that the share price remains 18.92% above its 200-day average of €38.69 suggests the longer-term trend is still intact.

Despite last week’s dip, Bayer has gained 24.32% since the start of the year, making it one of the better-performing DAX stocks in what many see as a turnaround story. Whether that momentum continues will likely depend on the twin outcomes of the August 4 earnings report and the August 19 court hearing — two events that together will either confirm or challenge the recovery narrative.